Marin Protein Hydrolysate and Metabolic Syndrome

Overview

Overweight and obesity are increasing global health problems and the most important contributors to morbidity and mortality. The maintenance of long-term weight loss is difficult, and individuals often regain weight after an intervention program is finished. It is of interest to find ways to prevent and alleviate metabolic syndrome (MetS), beyond the known effects of lifestyle modification and weight loss. Fish has been proposed as a food that may have favorable effects on metabolic health. There is evidence that cod, and other marine fish, may contain bioactive peptides that have potentially important health effects in humans. The aim of this study is to investigate the effect of adding a marine protein hydrolysate (MPH) supplement to the diet over an 8-week period in a group of adults with established MetS. The investigators expect that this will lead to beneficial changes in the components of MetS and to an overall healthier metabolic profile.

Full Title of Study: “The Effect of Supplementation With a Marine Protein Hydrolysate in Patients With Metabolic Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: December 31, 2019

Detailed Description

Overweight and obesity are increasing global health problems and the most important contributors to morbidity and mortality. Obesity (abdominal obesity), together with hyperglycemia, dyslipidemia and hypertension forms a cluster of risk factors that is called the metabolic syndrome (MetS). The first-line therapy for MetS is lifestyle intervention - education on a healthy lifestyle leading to a focus on physical activity and diet, which will improve risk factors closely linked to MetS. The maintenance of long-term weight loss is difficult, and individuals often regain weight after an intervention program stops. It is of interest to find ways to prevent and alleviate MetS, beyond the known effects of lifestyle modification and weight loss. Fish has been proposed as a food that may have favorable effects on metabolic health. Previous intervention studies with fish protein in humans and rodents have shown improved insulin sensitivity and glucose tolerance, reduced cholesterol levels in plasma and reduced blood pressure. Intervention studies investigating the effect of cod have mainly focused on the health effect of consuming the whole fillet. Studies on the remaining part of the fish, the residual material, primarily used for production of animal feed, are scarce. There is evidence that cod, and other marine fish, may contain bioactive peptides that have potentially important health effects in humans. Therefore, it is of interest to investigate the possible effect of a daily supplement of marine protein hydrolysate (MPH), taken over a longer period, in a group of patients with abnormal glucose control. The aim of this study is to investigate the effect of adding a MPH supplement to the diet over an 8-week period in a group of adults with established MetS. The investigators expect that supplementation with MPH will lead to beneficial changes in the components of MetS and an overall healthier metabolic profile.

Interventions

  • Dietary Supplement: MPH_active
    • One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
  • Dietary Supplement: MPH_placebo
    • One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.

Arms, Groups and Cohorts

  • Active Comparator: MPH_active
    • Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
  • Placebo Comparator: MPH_placebo
    • Daily intake at breakfast of supplementary placebo. Random sequence of arms.

Clinical Trial Outcome Measures

Primary Measures

  • Glucose
    • Time Frame: At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples every 20 minutes (i.e. -15, 0, 20, 40, 60, 80, 100,120 minutes after baseline).
    • Postprandial glucose (mmol/L) change at baseline and after 8 weeks on intervention.

Secondary Measures

  • Insulin
    • Time Frame: At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples every 20 minutes (i.e. -15, 0, 20, 40, 60, 80, 100,120 minutes after baseline).
    • Postprandial insulin (mmol/L) change at baseline and after 8 weeks on intervention.
  • Hormon hunger 1
    • Time Frame: At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples (i.e – 15, 0, 20, 40, 80, 120 minutes after baseline).
    • Glucagon like peptide 1 (GLP-1) pmol/l at baseline and after 8 weeks on intervention.
  • Hormon hunger 2
    • Time Frame: At baseline and after 8 weeks, the first sample fasted, thereafter repeated samples (i.e – 15, 0, 20, 40, 80, 120 minutes after baseline).
    • Ghrelin at baseline and after 8 weeks on intervention.
  • Body composition 1
    • Time Frame: At baseline and after 8 weeks.
    • Bioimpedance at baseline and after 8 weeks on intervention.
  • Body composition 2
    • Time Frame: At baseline and after 8 weeks.
    • Body mass index at baseline and after 8 weeks on intervention.
  • Body composition 3
    • Time Frame: First at baseline and after 8 weeks.
    • Waist circumference at baseline and after 8 weeks on intervention.
  • Glucose_met
    • Time Frame: At baseline and after 8 weeks.
    • Glycated hemoglobin (HBA1c) at baseline and after 8 weeks on intervention.

Participating in This Clinical Trial

Inclusion Criteria

Age 40-70 years

  • BMI 27-35 kg/m2 – Signed informed consent – MetS as defined by the presence of at least 3 of the 5 following criteria*: – Elevated waist circumference ≥ 94 cm (M), ≥ 80 cm (F) – Elevated triglycerides ≥ 1.7 mmol/L (150 mg/dL) – Elevated fasting glucose ≥ 5.5 mmol/L (100 mg/dL) – Elevated blood pressure S ≥ 130 and/or D ≥85 mmHg – Reduced HDL-cholesterol < 1.0 mmol/L (40 mg/dL) (M) <1.3 mmol/L (50 mg/dL) (F) – The International Diabetes Foundations (IDF) cut-off points are used. Exclusion Criteria:

  • Suspected allergy against fish or shellfish – Acute infections (may be reconsidered for inclusion at a later time) – Chronic disease or therapies that is likely to interfere with the evaluation study results – Pregnancy, lactation or planning pregnancy during study period – Substance misuse – Inability or unwillingness to comply with the requirements of study procedures

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Helse Møre og Romsdal HF
  • Collaborator
    • Haukeland University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dag Arne Lihaug Hoff, MD, PhD, Study Director, Helse Møre og Romsdal Hospital Trust

References

Jensen C, Dale HF, Hausken T, Hatlebakk JG, Bronstad I, Lied GA, Hoff DAL. The Effect of Supplementation with Low Doses of a Cod Protein Hydrolysate on Satiety Hormones and Inflammatory Biomarkers in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients. 2020 Nov 8;12(11):3421. doi: 10.3390/nu12113421.

Citations Reporting on Results

Jensen C, Fjeldheim Dale H, Hausken T, Hatlebakk JG, Bronstad I, Lied GA, Hoff DAL. Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study. Nutrients. 2020 Jul 4;12(7):1991. doi: 10.3390/nu12071991.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.